Evaxion A/S — Investor Relations & Filings

Evaxion A/S is a clinical-stage TechBio company specializing in the development of immunotherapies using its proprietary, clinically validated AI-Immunology™ platform. The platform leverages artificial intelligence and machine learning to decode the human immune system, enabling the rapid discovery and design of novel vaccine targets. Evaxion focuses on creating personalized and precision vaccines for the treatment of cancer and infectious diseases. Its pipeline includes personalized cancer vaccines in clinical development, such as EVX-01 for melanoma, and a preclinical portfolio targeting infectious diseases. The company's technology aims to accelerate the development of tailored vaccine candidates to address critical diseases.